Bruce M Spiegelman

This inventor holds 43 USPTO granted patents and 7 published patent applications, plus 4 CIPO patents and 7 EPO patents, primarily in Metabolic Disorders. Top assignees: Dana-Farber-Cancer Institute Inc., The Salk Institute, Duke University. Active years: 1992-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Bruce M Spiegelman. Retrieved from https://idiyas.com/inventor/bruce-m-spiegelman

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 43 (Patent Applications = 7)

% Patents Active = 81.4

CIPO Patents = 4 (Patent Applications = 4)

EPO Patents = 7 (Patent Applications = 5)

Average Co-Inventor Count = 2.5

ph-index = 11

Forward Citations = 345(Granted Patents)

Location History:

Newton, MA (US) (1992 - 1993)
Waban, MA (US) (1994 - 2023)

Company Filing History:

39 out of 1,268

Dana-Farber-Cancer Institute Inc.

Joslin Diabetes Center, Inc.

patents

6. 1 out of 6,961

Sumitomo Chemical Company, Limited

patents

7. 1 out of 80

The Beth Israel Hospital Association

patents

8. 1 out of 3,052

University of Florida Research Foundation Inc.

patents

9. 1 out of 834,513

Other

patents

where one patent can have more than one assignee

Years Active: 1992-2026

Loading Chart...

Areas of Expertise:

Metabolic Disorders

Brown Fat Differentiation

PGC-1 Modulation

Insulin Resistance

Tumor Cell Growth

Adipsin Regulation

Neurological Disorders

Thermogenesis

Energy Expenditure

Lipid-Related Diseases

Glucose Metabolism

Metrnl

43 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12702694 - METHODS FOR IDENTIFICATION, ASSESSMENT, PREVENTION, AND TREATMENT OF METABOLIC DISORDERS USING SLIT2 (2026-08-11),

2. 12194080 - Methods for identification, assessment, prevention, and treatment of metabolic disorders using PM20D1 and N-lipidated amino acids (2025-01-14),

3. 11766471 - Compositions and methods for induced brown fat differentiation (2023-09-26),

4. 11365177 - Chemical uncouplers of respiration and methods of use thereof (2022-06-21),

5. 11331379 - Compositions and methods for regulating pancreatic beta cell function using adipsin (2022-05-17),

6. 11291706 - Methods for identification, assessment, prevention, and treatment of metabolic disorders using Slit2 (2022-04-05),

7. 11129879 - Methods for the treatment of neurological disorders and diseases using FNDC5 (2021-09-28),

8. 11098092 - Compositions and methods for brown fat induction and activity using FNDC5 (2021-08-24),

9. 10717992 - Compositions and methods for regulating thermogenesis and muscle inflammation using metrnl and metrn (2020-07-21),

10. 10429384 - Compositions, kits, and methods for identification, assessment, prevention, and therapy of metabolic disorders (2019-10-01),

11. 10328131 - Compositions and methods for regulating pancreatic beta cell function using adipsin (2019-06-25),

12. 10286042 - Methods for the treatment of neurological disorders and diseases using FNDC5 (2019-05-14),

13. 10093705 - Compositions and methods for brown fat induction and activity using FNDC5 (2018-10-09),

14. 9181315 - Compositions and methods for induced brown fat differentiation (2015-11-10),

15. 9074012 - Molecular control of brown fat differentiation and energy expenditure (2015-07-07),

Title: The Innovative Journey of Bruce M. Spiegelman

Introduction: Bruce M. Spiegelman, a distinguished inventor hailing from Waban, MA (US), has made significant contributions to the field of innovations and inventions.

Latest Patents: Bruce M. Spiegelman holds several patents in the areas of biotechnology and medical research, showcasing his commitment to advancing scientific knowledge and technology.

Career Highlights: With a career spanning several decades, Bruce M. Spiegelman has been at the forefront of groundbreaking research in the fields of genetics, metabolism, and obesity. His work has not only garnered recognition within the scientific community but has also led to practical applications in the healthcare industry.

Collaborations: Throughout his career, Bruce M. Spiegelman has collaborated with leading researchers, scientists, and institutions to further his research and bring his innovative ideas to life. His collaborative spirit has been instrumental in pushing the boundaries of scientific discovery.

Conclusion: Bruce M. Spiegelman's dedication to innovation and his pioneering work in biotechnology and medical research have solidified his reputation as a visionary inventor. His contributions continue to inspire future generations of inventors and researchers in their quest to make the world a better place through groundbreaking discoveries.

Profile summary based on public USPTO records.